The urinary exosomal WT-1 (Wilms’ tumor-1) has been indicated as a promising noninvasive biomarker with podocyte specificity that can detect early progression and treatment-induced regression of podocyte injury in focal segmental glomerulosclerosis (FSGS) or steroid-sensitive nephrotic syndrome (SSNS) patients [27]. The gene discussed is WT1; the disease is focal segmental glomerulosclerosis.